Growth Metrics

Arrowhead Pharmaceuticals (ARWR) Other Working Capital Changes (2016 - 2025)

Arrowhead Pharmaceuticals' Other Working Capital Changes history spans 16 years, with the latest figure at $163.4 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 27494.43% year-over-year to $163.4 million; the TTM value through Dec 2025 reached $165.2 million, up 4366.36%, while the annual FY2025 figure was $2.4 million, 7.1% up from the prior year.
  • Other Working Capital Changes reached $163.4 million in Q4 2025 per ARWR's latest filing, up from -$19.9 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $163.4 million in Q4 2025 to a low of -$76.2 million in Q1 2023.
  • Average Other Working Capital Changes over 5 years is $8.1 million, with a median of $167609.0 recorded in 2021.
  • Peak YoY movement for Other Working Capital Changes: crashed 123289.91% in 2023, then soared 27494.43% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$27.4 million in 2021, then grew by 16.25% to -$23.0 million in 2022, then skyrocketed by 96.23% to -$866000.0 in 2023, then soared by 168.36% to $592000.0 in 2024, then skyrocketed by 27494.43% to $163.4 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Other Working Capital Changes are $163.4 million (Q4 2025), -$19.9 million (Q3 2025), and $1.4 million (Q2 2025).